Covaxin SARS-CoV-2 Vaccine Description
Bharat Biotech’s Covaxin is an inactivated SARS-CoV-2 vaccine candidate. The SARS-CoV-2 virus strain was isolated from an asymptomatic COVID-19 patient at NIV, Pune. It was then transferred to the Company which grew and replicated the virus.
The vector used in this new vaccine is a deactivated rabies vaccine that is known to produce a strong immune response, and that has been proven safe for all populations including children and pregnant women.
“Since we know the immune system reacts to the rabies vaccine with a strong response when we add the coronavirus component, we expect to see that level of protection, and immune memory, carry over to the SARS-CoV-2 viral protein as well," said Infectious Diseases expert Professor Matthias Schnell, whose lab developed the vaccine in January 2020, and has recently completed preliminary tests in animal models.
The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.
Bharat Biotech creates innovative vaccines and bio-therapeutics trusted by physicians around the world. We own 160 global patents and our products help people in over 65 countries live to their fullest potential.
Covaxin SARS-CoV-2 Vaccine Indication
The Covaxin vaccine is indicated to prevent infection from the SARS-CoV-2 virus that causes COVID-19 disease.
Covaxin SARS-CoV-2 Vaccine News
June 29, 2020 - India's Covaxin has received permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response.
May 20, 2020 - Bharat Biotech and Thomas Jefferson University of Philadelphia have signed an exclusive deal to develop a new vaccine candidate for COVID-19 invented at Jefferson. The novel vaccine was developed using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins.
May 8, 2020 - The Council of Scientific and Industrial Research (CSIR) under its flagship program NMITLI has sanctioned a project to develop human monoclonal antibodies as therapy for COVID-19 infections. The project is being led by Bharat Biotech, a leading manufacturer of vaccines and biotherapeutics as well as a supplier of products to over 65 countries in the world.
Covaxin SARS-CoV-2 Vaccine Clinical Trial
Human clinical trials are scheduled to start across India in July 2020.